216 related articles for article (PubMed ID: 27551051)
61. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
62. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
63. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors.
Garuti G; Cellani F; Centinaio G; Montanari G; Nalli G; Luerti M
Gynecol Oncol; 2006 Nov; 103(2):599-603. PubMed ID: 16750259
[TBL] [Abstract][Full Text] [Related]
64. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P
Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
[TBL] [Abstract][Full Text] [Related]
65. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
66. Summary of aromatase inhibitor trials: the past and future.
Goss P; von Eichel L
J Steroid Biochem Mol Biol; 2007; 106(1-5):40-8. PubMed ID: 17627816
[TBL] [Abstract][Full Text] [Related]
67. Preventing adverse events of chemotherapy by educating patients about the nocebo effect (RENNO study) - study protocol of a randomized controlled trial with gastrointestinal cancer patients.
Quidde J; Pan Y; Salm M; Hendi A; Nilsson S; Oechsle K; Stein A; Nestoriuc Y
BMC Cancer; 2018 Sep; 18(1):916. PubMed ID: 30249191
[TBL] [Abstract][Full Text] [Related]
68. Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer.
Boccardo F
Clin Breast Cancer; 2004 Sep; 5 Suppl 1():S13-7. PubMed ID: 15347434
[TBL] [Abstract][Full Text] [Related]
69. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Fallowfield LJ; Leaity SK; Howell A; Benson S; Cella D
Breast Cancer Res Treat; 1999 May; 55(2):189-99. PubMed ID: 10481946
[TBL] [Abstract][Full Text] [Related]
70. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
71. Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.
Nabieva N; Fehm T; Häberle L; de Waal J; Rezai M; Baier B; Baake G; Kolberg HC; Guggenberger M; Warm M; Harbeck N; Wuerstlein R; Deuker JU; Dall P; Richter B; Wachsmann G; Brucker C; Siebers JW; Popovic M; Kuhn T; Wolf C; Vollert HW; Breitbach GP; Janni W; Landthaler R; Kohls A; Rezek D; Noesselt T; Fischer G; Henschen S; Praetz T; Heyl V; Kühn T; Krauss T; Thomssen C; Hohn A; Tesch H; Mundhenke C; Hein A; Hack CC; Schmidt K; Belleville E; Brucker SY; Kümmel S; Beckmann MW; Wallwiener D; Hadji P; Fasching PA
Eur J Cancer; 2018 Jun; 96():82-90. PubMed ID: 29679775
[TBL] [Abstract][Full Text] [Related]
72. The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer.
Van Asten K; Poppe A; Punie K; Jongen L; Lintermans A; Wildiers H; Neven P
Curr Treat Options Oncol; 2015 Jul; 16(7):31. PubMed ID: 26031545
[TBL] [Abstract][Full Text] [Related]
73. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.
Fontein DB; Seynaeve C; Hadji P; Hille ET; van de Water W; Putter H; Kranenbarg EM; Hasenburg A; Paridaens RJ; Vannetzel JM; Markopoulos C; Hozumi Y; Bartlett JM; Jones SE; Rea DW; Nortier JW; van de Velde CJ
J Clin Oncol; 2013 Jun; 31(18):2257-64. PubMed ID: 23610112
[TBL] [Abstract][Full Text] [Related]
74. Clinical management of adverse events in adjuvant therapy for hormone-responsive early breast cancer.
Monnier A
Ann Oncol; 2007 Sep; 18 Suppl 8():viii36-44. PubMed ID: 17890213
[TBL] [Abstract][Full Text] [Related]
75. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Ganz PA; Cecchini RS; Julian TB; Margolese RG; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):857-65. PubMed ID: 26686960
[TBL] [Abstract][Full Text] [Related]
76. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
Cuzick J; Sestak I; Cella D; Fallowfield L;
Lancet Oncol; 2008 Dec; 9(12):1143-8. PubMed ID: 18976959
[TBL] [Abstract][Full Text] [Related]
77. [Menopausal symptoms and quality of life of hormone receptor positive breast cancer patients at different endocrine therapy time].
Li X; Wang H; Xu HP; Diao S; Zhou YW; Yi F; Li H; Li JC; Hao Y; Li JY
Zhonghua Zhong Liu Za Zhi; 2020 Jan; 42(1):55-60. PubMed ID: 32023770
[No Abstract] [Full Text] [Related]
78. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer.
Franzoi MA; Agostinetto E; Perachino M; Del Mastro L; de Azambuja E; Vaz-Luis I; Partridge AH; Lambertini M
Lancet Oncol; 2021 Jul; 22(7):e303-e313. PubMed ID: 33891888
[TBL] [Abstract][Full Text] [Related]
79. Possible alleviation of symptoms and side effects through clinicians' nocebo information and empathy in an experimental video vignette study.
Meijers MC; Stouthard J; Evers AWM; Das E; Drooger HJ; Jansen SJAJ; Francke AL; Plum N; van der Wall E; Nestoriuc Y; Dusseldorp E; van Vliet LM
Sci Rep; 2022 Sep; 12(1):16112. PubMed ID: 36167876
[TBL] [Abstract][Full Text] [Related]
80. Symptom Map of Endocrine Therapy for Breast Cancer: A Scoping Review.
Zhu Y; Cohen SM; Rosenzweig MQ; Bender CM
Cancer Nurs; 2019; 42(5):E19-E30. PubMed ID: 30138143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
